Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Allo-HSCT with DLI for Advanced CTCL
NCT02548468Phase 1Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2015
- Primary completion
- Jan 2017
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of T-cell-depleted donor lymphocyte infusion in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Rate of regimen-related toxicities at 100 days, Rate for hematopoietic engraftment at 100 days and 3 more. Planned start Nov 2015; status: withdrawn.
02
Drugs
T-cell-depleted donor lymphocyte infusion
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT02548468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548468.